Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
The drug contributes over half of the company's pharmaceutical revenues. Keytruda has played an instrumental role in driving Merck's steady revenue growth over the past few years, with sales of $23.3 billion in the first nine months of 2025 representing an 8% year-over-year increase. Though Keytruda sales increased 8% year over year during the third quarter of 2025, they were weaker than expected. Per management, Keytruda's soft sales in the third quarter were due to unfavorable channel movements and not due to a drop in underlying demand. Building on this optimism, we expect investors to focus on the sales performance of Keytruda when Merck reports its fourth-quarter and full-year 2025 results on Feb. 3. Keytruda sales are likely to have gained from rapid uptake across earlier-stage indications and strong momentum in metastatic indications in the fourth quarter. The company expects continued growth from Keytruda, particularly in the early lung cancer indication. The Zacks Conse
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]Yahoo! Finance
- Is Merck Stock A Trap At $110? [Forbes]Forbes
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]Yahoo! Finance Canada
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]Yahoo! Finance
- Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- MRK's page on the SEC website